Foxy-5 TFA
PRODUCTS SPECIFICATIONS
DESCRIPTION
Overview
| MDL | - |
|---|---|
| Molecular Weight | 808.80 |
| Molecular Formula | C28H43F3N6O14S2 |
| SMILES | - |
Summary
Foxy-5 TFA, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model [1] [2] [3] [4] .
IC50 & Target
WNT5A [1]
In Vivo
Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model
[1]
.
Foxy-5 reduces the number of colonic cancer stem cells in a xenograft mouse model of human colonic cancer
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02020291 | WntResearch AB |
Metastatic Breast Cancer|Colorectal Cancer|Prostate Cancer
|
June 2013 | Phase 1 |
| NCT03883802 | WntResearch AB|SMS-Oncology BV|SAGA diagnostics AB|Unilabs A+S|BioVica AB|Institut Català d´Oncologia |
Colon Cancer
|
April 12, 2019 | Phase 2 |
| NCT02655952 | WntResearch AB |
Metastatic Breast Cancer|Metastatic Colon Cancer|Metastatic Prostate Cancer
|
April 2016 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Sealed storage, away from moisture
| Powder | -80°C | 2 years |
|---|---|---|
| -20°C | 1 year |
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : 20 mg/mL ( 24.73 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.2364 mL | 6.1820 mL | 12.3640 mL |
| 5 mM | 0.2473 mL | 1.2364 mL | 2.4728 mL |
| 10 mM | 0.1236 mL | 0.6182 mL | 1.2364 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 7.14 mg/mL (8.83 mM); Clear solution; Need ultrasonic
References
- [1] Säfholm A, et al. The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin Cancer Res. 2008 Oct 15;14(20):6556-63.
- [2] Osman J, et al. The WNT5A Agonist Foxy5 Reduces the Number of Colonic Cancer Stem Cells in a Xenograft Mouse Model of Human Colonic Cancer. Anticancer Res. 2019 Apr;39(4):1719-1728.
- [3] Canesin G, et al. Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. PLoS One. 2017 Sep 8;12(9):e0184418.
- [4] Kelsey R. Prostate cancer: Foxy-5 in prostate cancer model. Nat Rev Urol. 2017 Nov;14(11):638.